BioPharmX to Present at Rodman & Renshaw 19th Annual Global Investment Conference
Sep 5, 2017
MENLO PARK, Calif., Sept. 5, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that Anja Krammer, president and co-founder of BioPharmX, will present at the Rodman & Renshaw 19th Annual Global Investment Conference next week.
Ms. Krammer is scheduled to present on September 12 from 3:25 – 3:50 p.m. EDT in the Louis Room at the Lotte New York Palace Hotel. A live webcast of the presentation will be available at
http://www.wsw.com/webcast/rrshq27/bpmx and will be archived for 90 days following the presentation.
The Rodman & Renshaw 19th Annual Global Investment Conference hosts approximately 200 public and private companies presenting to an audience of approximately 2,000 attendees. The conference focuses on tracks dedicated to healthcare, natural resources, technology, media and telecommunications, and cleantech.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding the safety and medical effects of BPX-01, the effect BPX-01 may have on the treatment of acne, the commencement and results of future trials of BPX-01 and the size of such trials, continued and consistent results in future tests of BPX-01 and absence of side effects of future use of BPX-01. These forward-looking statements may be identified by words such as "plan," "expect," "anticipate," "believe" or similar expressions that are intended to identify such forward-looking statements.
These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the period ended Jan. 31, 2017 and our quarterly report on Form 10-Q for the period ended April 30, 2017. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof, and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
BioPharmX is a registered trademark of BioPharmX, Inc.
SOURCE BioPharmX Corporation
For further information: For further information: Nina Brauer, Senior Manager, Marketing & Communications, email@example.com, (650) 889-5030 or Investors, firstname.lastname@example.org